APA (7th ed.) Citation

Ikegami, T., Honda, A., Kohjima, M., Miyazaki, T., Yara, S., Matsuzaki, Y., . . . Hirayama, T. (2018). Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. Internal Medicine, 57(9), 1219-1227. https://doi.org/10.2169/internalmedicine.9479-17

Chicago Style (17th ed.) Citation

Ikegami, Tadashi, Akira Honda, Motoyuki Kohjima, Teruo Miyazaki, Sho-Ichiro Yara, Yasushi Matsuzaki, Makoto Nakamuta, and Takeshi Hirayama. "Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment." Internal Medicine 57, no. 9 (2018): 1219-1227. https://doi.org/10.2169/internalmedicine.9479-17.

MLA (9th ed.) Citation

Ikegami, Tadashi, et al. "Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment." Internal Medicine, vol. 57, no. 9, 2018, pp. 1219-1227, https://doi.org/10.2169/internalmedicine.9479-17.